Skip to main content

Table 1 Demographic and baseline characteristics between groups in each Section (n = 30 for each group)

From: Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease

Variables Section 1 Section 2
Liraglutide monotherapy Metformin monotherapy P Liraglutide (1.8 mg/d) monotherapy Liraglutide plus Metformin dual therapy P
Male, n (%) 16 (53.3) 17 (46.7) 0.795 16 (53.3) 17 (46.7) 0.795
Duration of diabetes (year) 8 ± 5 7 ± 4 0.396 8 ± 5 9 ± 6 0.486
Age at initial visit (year) 58 ± 15 59 ± 17 0.810 58 ± 16 57 ± 14 0.798
Pre-medication       
 Statins (n) 2 3 0.640 4 4 1.000
 Fibrates (n) 2 1 0.554 3 2 0.640
 ARB (n) 4 3 0.688 5 5 1.000
 ACEI (n) 1 2 0.554 1 0 0.313
 Calcium antagonists (n) 2 2 1.000 2 3 0.640
 Diuretics (n) 0 0 0 1 0.313
BMI (kg/m2) 29.56 ± 1.68 29.63 ± 1.75 0.875 29.78 ± 1.85 29.66 ± 1.78 0.799
FPG (mmol/L)
HbA1c
9.3 ± 1.7 9.1 ± 2.0 0.678
0.749
9.0 ± 2.1 9.3 ± 1.7 0.546
0.758
 % 9.0 ± 1.3 9.1 ± 1.1   9.3 ± 1.3 9.4 ± 1.2  
 mmol/L 75 ± 14 76 ± 12 78 ± 14 79 ± 13  
PPG (mmol/L) 13.8 ± 5.1 13.7 ± 4.8 0.938 13.8 ± 4.9 13.6 ± 5.3 0.880
CRP (mg/L) 9.5 ± 2.2 9.7 ± 2.4 0.738 9.5 ± 2.2 9.7 ± 2.4 0.738
TG (mmol/L) 2.8 ± 0.7 2.9 ± 0.6 0.555 2.8 ± 0.6 2.9 ± 0.8 0.586
TC (mmol/L) 6.2 ± 0.8 6.3 ± 0.9 0.651 6.4 ± 0.8 6.3 ± 0.7 0.608
LDL-C (mmol/L) 4.1 ± 0.8 4.2 ± 0.7 0.608 4.3 ± 0.8 4.2 ± 0.7 0.608
SBP (mmHg) 145 ± 9 144 ± 8 0.651 146 ± 7 144 ± 8 0.307
DBP (mmHg) 92 ± 5 93 ± 7 0.527 94 ± 8 93 ± 7 0.608
LVEDD (mm) 55 ± 7 56 ± 9 0.633 59 ± 7 58 ± 9 0.633
EF (%) 48 ± 5 47 ± 4 0.396 46 ± 5 47 ± 4 0.396
E/A ratio 0.75 ± 0.09 0.72 ± 0.07 0.155 0.73 ± 0.06 0.75 ± 0.07 0.240
  1. Data are mean ± SD, unless otherwise noted; Abbreviations: BMI body mass index, TG triglyceride, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, PPG postprandial glucose, SBP systolic blood pressure, DBP diastolic blood pressure, CRP C-reactive protein, LVEDD left ventricular end-diastolic diameter, EF ejection fraction